Godard Sophie, Getz Gad, Delorenzi Mauro, Farmer Pierre, Kobayashi Hiroyuki, Desbaillets Isabelle, Nozaki Michimasa, Diserens Annie-Claire, Hamou Marie-France, Dietrich Pierre-Yves, Regli Luca, Janzer Robert C, Bucher Philipp, Stupp Roger, de Tribolet Nicolas, Domany Eytan, Hegi Monika E
Laboratory of Tumor Biology and Genetics,University Hospital (CHUV), 1011 Lausanne, Switzerland.
Cancer Res. 2003 Oct 15;63(20):6613-25.
The development of targeted treatment strategies adapted to individual patients requires identification of the different tumor classes according to their biology and prognosis. We focus here on the molecular aspects underlying these differences, in terms of sets of genes that control pathogenesis of the different subtypes of astrocytic glioma. By performing cDNA-array analysis of 53 patient biopsies, comprising low-grade astrocytoma, secondary glioblastoma (respective recurrent high-grade tumors), and newly diagnosed primary glioblastoma, we demonstrate that human gliomas can be differentiated according to their gene expression. We found that low-grade astrocytoma have the most specific and similar expression profiles, whereas primary glioblastoma exhibit much larger variation between tumors. Secondary glioblastoma display features of both other groups. We identified several sets of genes with relatively highly correlated expression within groups that: (a). can be associated with specific biological functions; and (b). effectively differentiate tumor class. One prominent gene cluster discriminating primary versus nonprimary glioblastoma comprises mostly genes involved in angiogenesis, including VEGF fms-related tyrosine kinase 1 but also IGFBP2, that has not yet been directly linked to angiogenesis. In situ hybridization demonstrating coexpression of IGFBP2 and VEGF in pseudopalisading cells surrounding tumor necrosis provided further evidence for a possible involvement of IGFBP2 in angiogenesis. The separating groups of genes were found by the unsupervised coupled two-way clustering method, and their classification power was validated by a supervised construction of a nearly perfect glioma classifier.
制定适用于个体患者的靶向治疗策略需要根据肿瘤的生物学特性和预后确定不同的肿瘤类别。在此,我们聚焦于这些差异背后的分子层面,即控制星形细胞瘤不同亚型发病机制的基因集。通过对53例患者活检样本(包括低级别星形细胞瘤、继发性胶质母细胞瘤(分别为复发性高级别肿瘤)和新诊断的原发性胶质母细胞瘤)进行cDNA阵列分析,我们证明人类胶质瘤可根据其基因表达进行区分。我们发现低级别星形细胞瘤具有最特异且相似的表达谱,而原发性胶质母细胞瘤在肿瘤之间表现出更大的变异性。继发性胶质母细胞瘤呈现出其他两组的特征。我们鉴定出几组在组内具有相对高度相关表达的基因,这些基因:(a). 可与特定生物学功能相关联;(b). 能有效区分肿瘤类别。一个区分原发性与非原发性胶质母细胞瘤的显著基因簇主要包含参与血管生成的基因,包括血管内皮生长因子(VEGF)fms相关酪氨酸激酶1,但也包括胰岛素样生长因子结合蛋白2(IGFBP2),该蛋白尚未直接与血管生成相关联。原位杂交显示IGFBP2和VEGF在肿瘤坏死周围的假栅栏状细胞中共表达,这为IGFBP2可能参与血管生成提供了进一步证据。通过无监督耦合双向聚类方法找到了区分不同组的基因,并且通过构建一个近乎完美的胶质瘤分类器的监督方法验证了它们的分类能力。